BECTON DICKINSON & CO (BDX): Results of Operations and Financial Condition
BECTON DICKINSON & CO (BDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.01 2 ex9916302026.htm EX-99.01 Document *Exhibit 99.1 1 Becton Drive Franklin Lakes, NJ 07417 www.bd.com Contacts: Investors: Shawn Bevec, SVP, Investor Relations - investor.relations@bd.com Media: Matt Marcus, VP, Public Relations - matt.marcus@bd.com BD Reports Third Quar
How this was made
The 30-second read
Why it matters
The key tradable items are Q3 outperformance versus expectations and the updated FY2026 guidance, including a higher adjusted diluted EPS midpoint and revenue growth toward the high end of the range.
Market read
This is a primary earnings-and-guidance disclosure with specific numbers and a guidance raise, which can drive same-day repricing and near-term positioning.
What to watch
The release emphasizes adjusted metrics; traders should scrutinize GAAP vs adjusted drivers, segment margin trends, and any assumptions embedded in the guidance range.
Background
BD completed the Feb 9, 2026 spin-off of Biosciences and Diagnostic Solutions and combined that business with Waters, and this 8-K reports results on a continuing-operations basis with recast prior periods.
Ticker impact
BDX reported fiscal Q3 results and updated full-year guidance, raising the midpoint of adjusted diluted EPS and expecting revenue growth toward the high end.
Near-term bias to the upside as traders reprice FY EPS and revenue growth expectations; follow-through depends on call commentary and segment margin details.
The filing includes specific Q3 EPS/revenue figures and a concrete guidance update (higher adjusted diluted EPS midpoint, revenue growth toward high end), which are direct inputs to valuation and positioning.
Market effects
Signals strength in medical technology demand and execution, potentially supportive for MedTech peers watching for similar margin and growth momentum.
International revenue growth remained positive, suggesting resilience beyond the US.
No direct global macro linkage beyond FX-neutral growth framing.
Counterpoint
Raised guidance could still be sensitive to execution risk, FX, and the ongoing integration effects of the Waters combination and spin-off restructuring.
Key entities
- companyBecton, Dickinson and Company
Medical technology company filing an 8-K with Q3 fiscal 2026 results and updated full-year guidance.
- executiveTom Polen
CEO and chairman quoted describing strong Q3 performance and early benefits of the more focused MedTech company.
- companyWaters Corporation
Referenced as the combination partner for the spun-off business, shaping the continuing-operations presentation.
